Physician profile
Neil Patel
NPI 1225448178
$2,041.59
in general payments reported to CMS, 2019-2025
21 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $131 · 2021: $339 · 2022: $415 · 2023: $539 · 2024: $318 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $968.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $864.50 | 2019-2024 | |
| Idorsia Pharmaceuticals US INC | $155.06 | 2022-2024 | Quviviq |
| Lilly USA, LLC | $138.39 | 2020-2025 | Mounjaro, Zepbound |
| Boston Scientific Corporation | $114.94 | 2020 | |
| Abbott Laboratories | $103.91 | 2021-2025 | Freestyle Libre 3 |
| Celgene Corporation | $100.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $95.61 | 2022-2025 | Fasenra, Bevespi Aerosphere, Farxiga |
| Pfizer INC. | $82.23 | 2021-2024 | |
| Dexcom, INC. | $57.33 | 2022-2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $52.83 | 2022-2024 | Wegovy, Saxenda |
| Vbi Vaccine (Delaware) INC. | $52.09 | 2022-2023 | Prehevbrio |
| Noven Therapeutics, LLC | $38.69 | 2023 | Xelstrym |
| Almatica Pharma LLC | $31.22 | 2024-2025 | Loreev Xr |
| Kowa Pharmaceuticals America, INC. | $30.55 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.94 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $19.77 | 2023 | Injectafer |
| Exact Sciences Corporation | $17.37 | 2024 | Cologuard Collection Kit |
| Noven Pharmaceuticals, INC. | $16.88 | 2023 | Xelstrym |
| Supernus Pharmaceuticals, INC. | $16.10 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.67 | 2022 | |
| Linus Health, INC. | $12.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.